Introduction
The oxytocin receptor (OTR) is a member of the G-protein coupled seven transmembrane receptor family, and mediates the physiological actions of the neurohypophysial nonapeptide hormone, oxytocin. The classical actions of oxytocin are to contract the uterus at parturition and to eject milk during lactation. Recently, it has been reported that oxytocin may also regulate various other functions such as sexual behaviour in female and male mammals, ovulation and ovum maturation, gonadal steroidogenesis, water metabolism and immune modulation. To mediate these actions, oxytocin receptors are expressed not only in reproductive tissues such as the uterus, mammary gland, ovary and testis but also in the central nervous system and other peripheral tissues such as kidney and thymus (Ivell and Russell, 1995) . The tissue distribution of OTR has mainly been characterized using ligand binding assays with labelled agonists or antagonists. Although there is no direct evidence for the existence of oxytocin isoreceptors (OTR subtypes), several reports have suggested the presence of multiple binding sites for OTR by differences in ligand binding selectivity between tissues (e.g. Chan et al., 1993) .
The recent cloning of OTR from several species indicates *Masahiko Kinoshita died tragically on June 9, 1995 during the progress of this project.
that OTR is a single copy gene with no evidence for any other closely related gene. From the deduced amino acid sequence of all the known OTR sequences, there are either three [human (Kimura et al., 1992) ; porcine (Gorbulev et al., 1993) ; bovine (Bathgate et al., 1995) ; and ovine (Riley et al., 1995) ] or two [rat (Rozen et al., 1995) and mouse (Kubota et al., 1996) ] putative N-linked glycosylation sites (Asn-X-Ser/Thr) in their N-terminal domains. In human uterus, the molecular weight of the OTR determined by immunoblotting (70 kDa) is considerably larger than the estimated molecular weight (43 kDa; Kimura et al., 1996) . In rat uterus, the molecular weight of the OTR treated with endoglycosidase F was~30 kDa smaller than the native receptor (Kojro et al., 1991) . These data suggest that the OTR is highly glycosylated when expressed in tissues.
It seems likely that the various N-terminal glycosylations on OTR may play a role in determining the differences in ligand selectivity and affinity sometimes observed in different tissues. Therefore, to determine what effect the individual glycosylations on the OTR has on its pharmacological character, we have established five HeLa cell derived stable cell lines expressing wild-type (wt) OTR and OTR molecules where potential N-glycosylation site(s) have been disrupted, using site-directed mutagenesis to substitute aspartic acid for asparagine in the different N-glycosylation motifs (Asn-X-Thr/Ser).
We have pharmacologically characterized these novel OTRexpressing cell lines and compared them with the native receptor in human term myometrium.
Materials and methods

Vector construction
The expression vector for wild-type human OTR (pRc/CMV-OTRwt) was constructed in pRc/CMV (Invitrogen, San Diego, CA, USA) as described elsewhere . OTR wt has three putative N-glycosylation sites at asparagine (N)8, N15 and N26. To disrupt these sites, we used various oligonucleotides to substitute aspartic acid (D) residues for asparagine (N) by changing the codon AAC (N8,N15,N26) to GAC (D8, D15) or GAT(D26) (Figure 1 ). To create a HaeII site between oligoN8/D8 and oligoN15/D15 to allow them to be ligated together, the codon for Ala 11 (GCC) was changed to GCt. To create a SmaI site at the end of oligo N15/D15 to allow it to be ligated to oligo D26/N26, the codon for Pro 21 (CCG) was substituted to CCc. For the easy recognition of D8 and D15 possessing clones, Ala 7 and Ala 14 (GCC) were exchanged to GCt to create PvuII sites. D26 was recognized by PvuI digestion (CGAtCG). The sense and antisense strands of oligonucleotides were synthesized as designed above (Figure 1 ). The 5Ј ends of both strands of oligo N8, oligo D8, oligo N15, oligo D15, oligo N26 and oligo D26 were phosphorylated with T 4 polynucleotide kinase (Toyobo, Osaka, Japan) and annealed to make the respective double-stranded oligonucleotides. Doublestranded (ds)-oligo N8 or D8 (which have restriction sites for HindIII at the 5Ј and HaeII at the 3Ј end), ds-oligo N15 or D15 (HaeII at the 5Ј and SmaI at the 3Ј end) and HindIII-SmaI digested pBluescript II KS ϩ (Stratagene, La Jolla, CA, USA) were ligated with T 4 DNA ligase (Toyobo). The plasmids were amplified, and HindIII-SmaI fragment were excised. The first 66 bp of the 5Ј untranslated region (nt-67-nt-2) of the pRc/CMV-OTRwt were deleted to create a HindIII site (aAGCTT) and an NcoI site (cCATGG) to permit ligation and recognition of the newly designed oligonucleotides. This vector was then digested with HindIII and SacII and then reconstructed to the entire receptor cDNA by ligation with the HindIII-SmaI fragment and ds-oligo N26 or D26. This strategy resulted in four mutants, namely OTR-D8N15N26, -N8D15N26, -N8D15D26 and -D8N15D26. The sequence of each clone was confirmed by the dideoxy chain termination method using the Sequenase kit (version 2.0; USB, Cleveland, OH, USA).
Transfection
HeLa cells (American Type Culture Collection, Rockville, MD, USA) were cultured in Ham's F12-Dulbecco's modified Eagle's medium (DMEM) (1:1) (Gibco BRL, Gaithersburg, MD, USA) supplemented with 10% heat-inactivated calf serum (Gibco BRL), penicillin (10 3 IU/ml), and streptomycin (100 µg/ml). The cells were plated out 24 h before transfection at a density of 2ϫ10 5 cells per 90 mm dish. A total of 60 µg of each plasmid DNA (pRc/CMV-OTRwt, OTR-D8N15N26, OTR-N8D15N26, OTR-N8D15D26 and OTR-D8N15D26; purified twice with CsCl gradient ultracentrifugation) were precipitated and transfected into HeLa cells using the conventional calcium-phosphate method (Sambrook et al., 1989) . Permanent transfectants of each clone were selected for their resistance to the antibiotic G418 (Gibco BRL) applied to the media at a concentration of 1 mg/ml.
Southern blotting
Transfected or native HeLa cells (5ϫ10 7 cells) were lysed in 0.5% sodium dodecyl sulphate (SDS), 10 mM Tris-HCl (pH 7.5), 1 mM 958 EDTA, 100 mM NaCl, and incubated with 50 µg/ml of proteinase K (Takara, Kyoto, Japan) at 50°C overnight. High molecular weight DNA was extracted with phenol-chloroform and precipitated with ethanol. In all, 5 µg of each DNA was completely digested by PstI, electrophoresed on a 0.9% agarose/1ϫ TAE gel, depurinated, denatured and capillary transferred onto a Nylon membrane (Hybond N; Amersham International, Amersham, Bucks, UK) with 20ϫ sodium chloride/sodium citrate (SSC). The filter was hybridized with α-[ 32 P]-dCTP labelled 0.4 kb PstI-PstI fragment of human OTR cDNA (Megaprime DNA labelling system; Amersham) in Quickhyb (Stratagene) supplemented with 100 µg/ml fragmented, heat-denatured salmon spermatozoa DNA at 65°C for 2 h. The filter was washed under high stringency conditions and exposed to a X ray film (Kodak XAR; Kodak, Rochester, NY, USA) at -70°C for 16 h.
Northern blotting
Total RNA was obtained from the transfected or native HeLa cells (5ϫ10 7 cells) by acid-guanidine-phenol-chloroform extraction (Chromczynski and Sacchi, 1987) . Poly(A)-enriched RNA was purified using oligo(dT)-latex beads (Oligotex-dT30; Takara) according to the manufacturer's instructions. One microgram of poly(A)-enriched RNA was resolved by denaturing 1.5% agarose gel electrophoresis and transferred onto a nylon membrane as described elsewhere . Hybridization of the blotted membrane using an [α-32 P]-dCTP labelled OTR cDNA probe was performed as described above for Southern blotting.
Radioreceptor binding assay
Approximately 10 8 stably transfected cells or 1 g of human term uterine myometrium (obtained from a uterus removed because of rupture at parturition) were homogenized in 20 ml of ice-cold 10 mM Tris-HCl (pH 7.5) containing 1.5 mM EDTA. The crude homogenates were centrifuged at 1000 g for 15 min at 4°C and the supernatants further centrifuged at 120 000 g for 30 min at 4°C. The pellets were resuspended in 50 mM Tris-HCl (pH 7.5), 5 mM MgCl 2 and the receptors assessed by radioligand binding as described elsewhere (Bathgate and Sernia, 1994) . Briefly, the reaction mixture consisted of 100 µl membrane suspension, 100 µl of 125 I-labelled OTA ([d(CH 2 ) 5 Tyr(Me) 2 Tyr 4 Tyr 9 -NH 2 ]-vasotocin, 2200 Ci/mmole; NEN DuPont, Bad Homburg, Germany; 15 000 c.p.m.), and 100 µl of various concentrations of unlabelled OTA (generous gift from Dr M.Manning) or agonists and antagonists in assay buffer [50 mM Tris-HCl, 2.5 mM MgCl 2 , 0.2% bovine serum albumin (BSA), pH 7.5]. Non-specific binding was determined in the presence of 40 pmol of unlabelled OTA. After incubation at room temperature for 2.5 h, the bound ligand was precipitated by the addition of 250 µl γ-globulin (4 mg/ ml) and 1.5 ml 16% (w/v) polyethylene glycol and centrifuged at 1500 g for 20 min. The pellet was counted in a γ-counter (LKB 1277; Pharmacia, Turku, Finland). Competition binding assays were performed on each cell line and compared with term myometrium using oxytocin, arginine vasopressin, [d(CH 2 ) 5 Tyr(Me) 2 ]-AVP, a specific V 1 receptor antagonist [courtesy of Dr M.Manning (Kruszynski et al., 1980) (Melin et al., 1986) ]. The dissociation constant (K d ) and 50% inhibition constant (IC 50 ) were calculated from two independent binding experiments where each data point was performed in triplicate. These experiments gave virtually identical results. The intra-and interassay coefficents of variation were 10 and 14% respectively.
Whole cell binding assay
Cells were grown in 90 mm dishes to 80% confluence at which time the cells were removed using 0.1% EDTA in Ca 2ϩ and Mg 2ϩ -free Figure 1 . Representation of the oligonucleotides used to construct the oxytocin receptor (OTR) mutants. Both strands of the oligonucleotides were synthesized by an automatic DNA synthesizer. Lower case letters indicate the nucleotide exchange within the same codon to produce cohesive restriction sites or to produce PvuII (oligo D8, oligo D15) or PvuI (oligoD26) sites for distinction from oligo N8, oligo N15 and oligo N26 respectively. pRc/CMV-OTR wild-type contains 67 bp upstream of the 5Ј untranslated OTR cDNA sequence until the first BamHI site. In the mutants, 66 bp of this 5Ј side was deleted to generate HindIII and NcoI sites therefore allowing ligation to the multicloning site of pRc/CMV and recognition of the new construct. The entire cDNA was reconstructed as described in the text. The sequences of the plasmids were determined by the dideoxy chain termination method (Sequenase version 2.0). 
Statistical analysis
Scatchard analysis was performed using the LIGAND programme (Munson and Robard, 1980) and competition curves were generated with non-linear regression analysis of the Graphpad Prism program (Graphpad Software Inc, San Diego, CA, USA).
Results
Southern and Northern blotting
As indicated in Figure 2A , wild-type HeLa cells bear only a single copy of the endogenous OTR gene. As the 0.4 kb PstIPstI fragment is split by a 13 kb intron (intron 3; Inoue et al., 1994), the signals for the native OTR gene were observed as 5 and 2.1 kb bands. In the transfectants, there was in addition to the endogenous signals, a 0.4 kb signal derived from the integrated OTR cDNA constructs. The relative intensities of these signals indicated that either one or two copies of the OTR cDNA were integrated in each cell line. Figure 2B indicates that all of the transformants expressed high amounts of the 1.6 kb OTR mRNA transcribed from the expression vectors. The mutations within the coding region or the deletion of the 5Ј non-coding region all had no significant effect on the level of the resulting transcripts.
Radioreceptor assay
All of the transfectants had single high affinity binding sites for [ 125 I]-OTA whereas no specific binding was observed in the native HeLa cells, indicating that the specific OTR binding originated exclusively from the transfected cDNA constructs. The K d of [ 125 I]-OTA binding for each clone were similar to one another (0.24-0.29 nM) and showed a marginally higher affinity than to term myometrium (0.33 nM). The rank order of affinities for the various OT-related ligands was OTAϾϭ OTϾAVPϾMCϾAtosiban with no obvious differences between the individual mutated clones, wild-type OTR cDNA or term myometrium (Table I and Figure 3) . Thus, the mutation of one or two potential N-glycosylation sites did not influence the ligand affinity and selectivity of the OTR. which, in vivo, is known to express the highest levels of OTR. The binding capacity in the cells per mg membrane fraction protein was higher than for uterine tissue of pregnancy. Sitespecific mutagenesis of the N-terminal extracellular domain, causing a selective loss of the three potential sites of Nglycosylation, affects neither the binding properties nor the binding capacity of the OTR. Furthermore, since a high amount of oxytocin binding was observed on the cell surface of each clone, this implied that the mutant receptors were being expressed normally on the cell surface.
The amino-terminus of most members of the seven transmembrane receptor family include one or more potential Nglycosylation consensus sequences, and these appear to be involved in ligand binding and/or receptor function. For example, in the gonadotrophin-releasing hormone (GnRH) receptor, disruption of the N-glycosylation site in the N-961 terminal domain caused a complete loss of ligand binding activity (Cook et al., 1993) . In β 2 -adrenergic receptors (Rands et al., 1990) and vasoactive intestinal peptide (VIP)-I receptors (Couvineau et al., 1996) , carbohydrate chains attached to the N-terminal domains are essential for correct trafficking of the receptor. On the other hand, N-glycosylation sites of the m 2 -muscarinic receptor (Koppen and Nathanson, 1990) , histamine H 2 receptor (Fukushima et al., 1995) , and vasopressin V 2 receptor (Innamorati et al., 1996) appear not to be essential for their ligand binding and function, although in the m 2 receptor, the affinity to some ligands was altered. For the follicle stimulating hormone (FSH) receptor, whose ligand FSH has a relatively high molecular weight and considerable glycosylation, disruption of N-glycosylation sites by mutagenesis appeared to affect receptor trafficking, whereas on the other hand, enzymatic deglycosylation of the cell surface receptor failed to alter the affinity for the ligand (Davis et al., 1995) . It thus seems likely that interactions between N-glycosyl carbohydrate side chains of receptors and their ligands are independent events. In the human OTR, we have now shown that the existence of N-glycosylation site(s) is not necessary for specific ligand binding. Also, because oxytocin binding on the cell surface was normal for each clone, we can infer that the receptor trafficking is probably not affected. We have not, however, examined more downstream events, such as G-protein coupling or signal transduction for these mutants. The doseresponse curve of inositol monophosphate (IP 1 ) accumulation in OTR-transfected 293 embryonic kidney cells (Jasper et al., 1995) is very similar to the dose-response curve of the membrane current in Xenopus laevis oocytes injected with OTR cRNA (Kimura et al., 1992) . It is widely observed that seven transmembrane receptor molecules interact with their signal transducer, G-proteins, with their third intracellular loops and C-terminal domains. The chimeric vasopressin V 2 receptor that possesses extracellular domains of OTR could activate adenylate cyclase and produce cAMP upon oxytocin stimulation (Postina et al., 1996 (Hausmann et al., 1996) . We therefore assume that the wild-type oxytocin receptor should possess the normal signal transduction pathway and that alterations in the extracellular N-terminal domain would be unlikely to affect the interaction between the intracellular parts of the receptor and G-proteins. Several authors have postulated that the OTR may be expressed in different isoforms (Maggi et al., 1990 (Maggi et al., , 1992 Pliska and Kohlhauf Albertin, 1991) . From the pharmacological responses of rat uterine tissue, Chan et al. (1993) suggested the existence of an additional OTR subtype. However no discrete OTR subtypes have ever been found by molecular cloning of OT receptors from a variety of species, even using low stringency hybridization procedures. It seems more likely that the pleiomorphism of the oxytocin receptor could be explained by post-translational variation, such as a differential pattern of glycosylation in the receptor N-terminal domain. However, the present data do not support this hypothesis. Recently, it has been reported that plasma membrane cholesterol content can markedly influence the ligand binding properties of OTR Klein et al., 1995) . Such observations would appear to offer a more plausible explanation for the OTR heterogeneity found in different tissue preparations.
In conclusion, we have established various stably transfected cell-lines which express the human OTR in higher amounts than term human myometrium. These cell lines could prove very useful in the pharmacological screening for oxytocinrelated products. As the glycosylation status of the receptor does not appear to influence receptor characteristics, it could also be feasible and legitimate to study the expression of the oxytocin receptor in cells from other species, such as in the baculovirus-insect cell system or even in yeast, where there may be quite different pathways for protein glycosylation.
